Skip to content
This GLP
By This GLP Editorial Team · Updated September 2026One price, two memberships

MEDVi review

Only one of three lines publishes what the medicine costs; on the other two the figure on the card is the membership and the drug is unpriced.

The verdict

MEDVi charges $179 for a first month of injected semaglutide and $299 a month for every refill after it, and that is the only line here carrying a medication price. Its other two show a $99 membership with the drug cost unstated, so this site ranks no figure for either.

Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.

Category
GLP-1 telehealth
Molecule
Semaglutide · Tirzepatide
Form
Injection · Oral
States
48
From
From $299/mo
Prescription
Required
Compounded
Yes — not FDA-approved
Availability
48 states

MEDVi sells injected semaglutide at a published refill rate alongside a Wegovy pill line and a branded Zepbound line, both of which advertise a membership rather than a price. A compounded tablet card names no molecule, and coverage runs across 48 states.

  1. Who writes the prescription, and what do they see?

    The $99 is what the clinical relationship costs on two of the three lines, and the pages state it plainly. What they do not state is what the medication then costs, which leaves the membership priced and the purchase unpriced.

    A membership model is legitimate and several sellers here use it well. What separates this one is that the medication figure is absent rather than merely separate, so a buyer pays $99 to discover a number that decides the whole purchase.

  2. What happens when the dose goes up?

    The semaglutide refill is described as locked in at $299, and the program states it includes the same benefits at every refill, though no milligram is attached to that promise. On the membership lines the dose question cannot even be asked, because no medication figure exists to move.

  3. What the price includes

    Six months of injected semaglutide is $1,674 at the published rates: $179 for the first month and five refills at $299. For the other two lines there is nothing to compute: $99 buys access and the drug is billed at a figure the pages describe as varying, with insurance possibly reimbursing some of it. Ask for that number before paying a membership, and treat a refusal as information.

  4. What it claims, and what it cites

    The semaglutide line is compounded, prepared to order by a pharmacy the pages do not name, and not reviewed by the FDA before dispensing. A compounded tirzepatide product previously published at $349 no longer appears anywhere on the seller's sites, so this site carries no figure for it rather than repeating a stale one.

Where it holds up, and where it does not

  • Strength: One line publishes a flat medication rate
  • Strength: The membership amount is stated clearly
  • Strength: Coverage across 48 states
  • Strength: The refill rate is printed beside the first-month offer
  • Limitation: Two lines publish no medication cost
  • Limitation: The membership is paid before the number appears
  • Limitation: A previously published line has disappeared
  • Limitation: Availability is described as subject to change

What the evidence says about this kind of treatment

The assessment above is about MEDVi. These are about the drugs it sells, and they are traced to the primary literature.

Right for
A reader who wants the injected semaglutide line, where the figure on the card is the figure for the medicine.
Wrong for
A reader considering the oral or branded routes, where nothing published says what the treatment itself costs.

The evidence behind what MEDVi prescribes

These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.

How MEDVi compares

SellerWho it suitsGo
He & She MDA reader with a year's cost available who wants the annual total printedSee He & She MD →
Try AgelessReaders willing to price the same product twice before buying it onceSee Try Ageless →
SkinnyRxReaders choosing tirzepatide, the one line with a published standing rateSee SkinnyRx →
Compare all providers side by side →

More GLP-1 telehealth sellers reviews: Call-On-DocCandor RxCare Bare RxCare ClinicsCarocare WellnessCeliaRx

Sponsored alternative

SkinnyRx

Readers choosing tirzepatide, the one line with a published standing rate

Check SkinnyRx availability →

Frequently asked

Why does this site show no price on two lines?
Because the $99 on those cards is a membership fee and the medication cost is not stated anywhere, so no total can be built from what is published.
What does injected semaglutide cost?
$179 for the first month and $299 for each refill after it. The refill rate is the one figure here a reader can plan against.
What happened to the compounded tirzepatide?
It is no longer published anywhere on the seller's sites or intake flow, so this site treats it as discontinued rather than carrying an older figure forward.
Is MEDVi legit?
MEDVi is a GLP-1 telehealth sellers service. Its stated availability: 48 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay.
Is MEDVi expensive compared with other GLP-1 telehealth sellers?
MEDVi publishes a starting figure of $299/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts MEDVi above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.
This GLP Editorial TeamPublisher · Updated September 2026

How this was assessed. The four questions above are answered from MEDVi’s own publicly-stated model, against the published editorial methodology. No ratings are fabricated and no first-hand outcomes are claimed. A partnership never changes the assessment — see how we make money.